Skip to content
HowShorted

Acorda Therapeutics, Inc. short interest in 2018

In 2018, Acorda Therapeutics, Inc.'s disclosed short interest ran from 11.88% of shares outstanding on 12 Jan 2018 to 16.82% on 31 Dec 2018, a change of +4.94 percentage points. The year's high was 17.04% on 30 Nov 2018 and its low 8.96% on 31 Aug 2018, averaging 12.85% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.58 days on 30 Apr 2018. Full history: Acorda Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Acorda Therapeutics, Inc. in 2018

2018 in figures

Start of year
11.88% (12 Jan 2018)
End of year
16.82% (31 Dec 2018)
Change
+4.94 pp
High
17.04% (30 Nov 2018)
Low
8.96% (31 Aug 2018)
Average
12.85%
Highest days to cover
21.58 (30 Apr 2018)
SEC filings marked
9

Every report in 2018

Acorda Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201811.88%6.63results (8-K)
31 Jan 201812.42%5.77
15 Feb 201812.96%11.10results (8-K)
28 Feb 201813.94%6.18
15 Mar 201813.23%11.9510-K filed
29 Mar 201813.41%13.93
13 Apr 201812.94%18.38
30 Apr 201812.90%21.58
15 May 201812.58%17.00results (8-K), 10-Q filed
31 May 201812.82%10.73
15 Jun 201811.90%4.80
29 Jun 201810.53%7.41
13 Jul 20189.03%11.00
31 Jul 20189.45%8.95
15 Aug 20189.47%10.77results (8-K), 10-Q filed
31 Aug 20188.96%13.58
14 Sep 201811.38%3.69
28 Sep 201812.87%6.64
15 Oct 201814.44%7.79
31 Oct 201815.03%8.39results (8-K)
15 Nov 201816.89%11.2310-Q filed
30 Nov 201817.04%19.00
14 Dec 201815.46%7.12
31 Dec 201816.82%7.97

See also: Acorda Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.